Trinity College Dublin

Skip to main content.

Top Level TCD Links

Neuropharmacology and New Drug Development

Neurology has an active cutting-edge research programme that is focused on developing novel pharmacotherapy for central nervous system (CNS) disorders involving neuronal injury and disturbances of neurobiological functions.

Currently, core research is centered on preclinical development of a novel lead neurotherapeutic compound (LC). LC has a unique groundbreaking design that enables the well-recognized, multifactorial, neurotherapeutic and homeostatic effects of the naturally-occurring neuropeptide thyrotrophin-releasing hormone (TRH) to be utilized in the clinic in ways that have not been previously possible. LC thereby offers an innovative multifunctional approach to the treatment of a wide range of CNS disorders, including acute and chronic neurodegenerative conditions, such as CNS trauma and Motor Neuron Disease (MND), and epilepsy. LC has been shown to provide significant and clinically relevant therapeutic benefit in several models of neurodegeneration, including MND and temporal lobe epilepsy, and has led to a series of novel and high impact findings in neuropharmacology.

Last updated 23 November 2016 Neurology (Email).